Emergent Biosolutions (EBS) Stock Price, Quote & News

Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botul...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 240 631 3200

Fax: 240 631 3203

Website: www.emergentbiosolutions.com

Address:

300 Professional Drive, Suite 400, Gaithersburg, United States

SolarWind99 Aug. 24 at 3:34 PM

$EBS Good to see Jessica still at it.

0 · Reply

USAEquityResearch Aug. 24 at 2:32 PM

$EBS 📊 USAEquityResearch ▲ 5.12 (+0.79%) Trend: Bearish 📉 RSI (14): 21.0 — oversold, potential bounce territory MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 7.57 | Support: 4.45 20-MA: 5.67 | 50-MA: 7.05 💼 Fundamentals Mkt Cap: $262.52M Fwd P/E: 4.9 FCF: $37.50M (0.73/sh) Total Debt: $588.20M D/E: 172.29 📉 Options (exp 2026-09-18) ATM IV: 62.1% | Skew: -0.8% (balanced) P/C Ratio: 0.49 🐂 Bullish lean Max Pain: 5.00 Call wall: 6.00 | Put wall: 5.00 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/EBS

0 · Reply

myman1956 Aug. 24 at 2:02 AM

$EBS Look for a dip at the open on Monday that could be a few taking profits like many always do.

0 · Reply

PetBac Aug. 22 at 9:05 AM

$EBS https://m.bild.de/unterhaltung/stars-und-leute/hayden-panettiere-ihre-letzten-minuten-on-off-freund-gab-ihr-nasenspray-6a892404c3692834ff6d8f9d

0 · Reply

Ithaca2018 Aug. 22 at 2:12 AM

$EBS So happy I added 2K $4.65

0 · Reply

KnuckleSandwich Aug. 21 at 9:48 PM

$EBS just like old time Ms Jes Fye is f’ing EBS?

0 · Reply

ComradeKomisar Aug. 21 at 8:13 PM

$EBS lol. That girl is somethig. Slaps a "sell" rating, but does not disclose a price target. Share price goes up merely on the whiff of resumption of institutional "coverage".

0 · Reply

USAEquityResearch Aug. 21 at 7:31 PM

$EBS 📊 USAEquityResearch ▲ 5.05 (+4.67%) Trend: Bearish 📉 RSI (14): 22.6 — oversold, potential bounce territory MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 7.57 | Support: 4.45 20-MA: 5.78 | 50-MA: 7.12 💼 Fundamentals Mkt Cap: $258.67M FCF: $37.50M (0.73/sh) Total Debt: $588.20M D/E: 172.29 📉 Options (exp 2026-09-18) ATM IV: 66.4% | Skew: +17.2% (put-heavy) P/C Ratio: 0.53 🐂 Bullish lean Max Pain: 5.00 Call wall: 6.00 | Put wall: 5.00 Educational content only. Not financial advice.

0 · Reply

Cinderblocks Aug. 21 at 7:31 PM

$EBS Looking good.. There's a gap to fill all the way to$7.

0 · Reply

STACKD0E Aug. 21 at 7:27 PM

$EBS $DFNS $GRML $CLF $RITR 👁

0 · Reply

Emergent BioSolutions reinstated with an Underweight at JPMorgan

Aug 17, 2026, 1:38 PM EDT - 6 days ago

EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law

Aug 11, 2026, 10:07 AM EDT - 13 days ago

EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions

2026-08-10T10:10:21.000Z - 14 days ago

Emergent BioSolutions price target lowered to $10 from $12 at H.C. Wainwright

Aug 5, 2026, 5:00 PM EDT - 18 days ago

Emergent BioSolutions Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 18 days ago

Emergent BioSolutions Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 18 days ago

Emergent BioSolutions Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 18 days ago

Emergent BioSolutions Quarterly report: Q2 2026

Aug 5, 2026, 4:07 PM EDT - 18 days ago

Emergent BioSolutions Reports Second Quarter 2026 Financial Results

Aug 5, 2026, 4:07 PM EDT - 18 days ago

Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment

Jul 22, 2026, 4:01 PM EDT - 4 weeks ago

Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-06-29T13:25:30.000Z - 2 months ago

Emergent BioSolutions awarded $52.7M contract modification

Jun 29, 2026, 9:13 AM EDT - 2 months ago

Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government

Jun 23, 2026, 8:00 AM EDT - 2 months ago

BioMendics Receives FDA Fast Track Designation for BM-3103 (TolaSure® Gel™) for Epidermolysis Bullosa Simplex

Jun 8, 2026, 2:00 PM EDT - 2 months ago

Emergent BioSolutions Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 8:02 AM EDT - 2 months ago

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Jun 3, 2026, 1:20 PM EDT - 2 months ago

Emergent BioSolutions Transcript: Jefferies Global Healthcare Conference 2026

2026-05-28T21:00:59.000Z - 3 months ago

Emergent BioSolutions awarded $64.5M HHS contract modification

May 28, 2026, 4:01 PM EDT - 3 months ago

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

May 20, 2026, 7:30 AM EDT - 3 months ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

2026-05-18T13:18:07.000Z - 3 months ago

Emergent BioSolutions receives Saudi approval for ACAM2000 vaccine

May 18, 2026, 8:59 AM EDT - 3 months ago

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

May 11, 2026, 7:53 AM EDT - 3 months ago

Hantavirus cases spark surge in pharma and biotech stocks — here's why

INO MRNA NVAX

Apr 30, 2026, 5:00 PM EDT - 4 months ago

Emergent BioSolutions Earnings Call Transcript: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 4 months ago

Emergent BioSolutions Earnings release: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 4 months ago

Emergent BioSolutions Slides: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 4 months ago

Emergent BioSolutions Quarterly report: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 4 months ago

Emergent BioSolutions Reports First Quarter 2026 Financial Results

2026-04-30T13:58:59.000Z - 4 months ago

Emergent BioSolutions receives Singapore regulatory approval for ACAM2000

Apr 30, 2026, 7:55 AM EDT - 4 months ago

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

Apr 29, 2026, 9:00 AM EDT - 4 months ago

Emergent BioSolutions Transcript: AGM 2026

2026-04-29T12:30:52.000Z - 4 months ago

Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

SABS

Apr 29, 2026, 7:35 AM EDT - 4 months ago

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

Apr 29, 2026, 6:53 AM EDT - 4 months ago

Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives

2026-04-28T12:59:14.000Z - 4 months ago

Emergent BioSolutions reports Imojev manufacturing pact with Substipharm

Apr 28, 2026, 8:01 AM EDT - 4 months ago

Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Apr 16, 2026, 4:05 PM EDT - 4 months ago

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

Apr 16, 2026, 4:05 PM EDT - 4 months ago

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing

2026-04-09T20:31:33.000Z - 4 months ago

Emergent BioSolutions teams with British Columbia on Take-Home Naloxone Program

Apr 9, 2026, 4:25 PM EDT - 4 months ago

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

Apr 7, 2026, 8:05 AM EDT - 4 months ago

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences

2026-03-25T20:26:40.000Z - 5 months ago

Emergent BioSolutions announces over $60M in government contract awards

Mar 25, 2026, 4:15 PM EDT - 5 months ago

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Mar 17, 2026, 12:49 PM EDT - 5 months ago

Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.

SIGA

2026-03-09T10:10:22.000Z - 6 months ago

Emergent BioSolutions price target lowered to $12 from $15 at H.C. Wainwright

2026-03-03T13:40:58.000Z - 6 months ago

Emergent BioSolutions appoints Fowler to board of directors

2026-03-03T13:27:16.000Z - 6 months ago

Emergent BioSolutions appoints Fowler to board of directors

Mar 3, 2026, 8:00 AM EST - 6 months ago

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

Feb 26, 2026, 5:00 PM EST - 6 months ago

Emergent BioSolutions Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Emergent BioSolutions Annual report: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Emergent BioSolutions Earnings release: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Emergent BioSolutions Slides: Q4 2025

Feb 26, 2026, 4:05 PM EST - 6 months ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 4:01 PM EST - 6 months ago

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness

Feb 26, 2026, 4:01 PM EST - 6 months ago

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

Feb 12, 2026, 6:00 PM EST - 6 months ago

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Feb 12, 2026, 9:02 AM EST - 6 months ago

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Jan 15, 2026, 1:08 PM EST - 7 months ago

NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading

Jan 14, 2026, 8:15 PM EST - 7 months ago

Emergent BioSolutions Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 7 months ago

Emergent BioSolutions Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 8 months ago

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

Jan 8, 2026, 4:30 PM EST - 8 months ago

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Jan 8, 2026, 8:00 AM EST - 8 months ago

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Jan 7, 2026, 7:59 AM EST - 8 months ago

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 12, 2025, 8:30 AM EST - 9 months ago

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

Nov 18, 2025, 8:00 AM EST - 9 months ago

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

Nov 12, 2025, 4:01 PM EST - 10 months ago

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Emergent BioSolutions Earnings Call Transcript: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Emergent BioSolutions Quarterly report: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Emergent BioSolutions Earnings release: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Emergent BioSolutions Slides: Q3 2025

Oct 29, 2025, 4:15 PM EDT - 10 months ago

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

Oct 8, 2025, 7:45 AM EDT - 11 months ago

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

Sep 24, 2025, 4:05 PM EDT - 11 months ago

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

Sep 19, 2025, 8:34 AM EDT - 1 year ago

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

Sep 15, 2025, 8:35 AM EDT - 1 year ago

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Sep 9, 2025, 7:30 AM EDT - 1 year ago

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Sep 4, 2025, 3:00 PM EDT - 1 year ago

Emergent BioSolutions Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 7:40 AM EDT - 1 year ago

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

SolarWind99 Aug. 24 at 3:34 PM

$EBS Good to see Jessica still at it.

0 · Reply

USAEquityResearch Aug. 24 at 2:32 PM

0 · Reply

myman1956 Aug. 24 at 2:02 AM

$EBS Look for a dip at the open on Monday that could be a few taking profits like many always do.

0 · Reply

PetBac Aug. 22 at 9:05 AM

$EBS https://m.bild.de/unterhaltung/stars-und-leute/hayden-panettiere-ihre-letzten-minuten-on-off-freund-gab-ihr-nasenspray-6a892404c3692834ff6d8f9d

0 · Reply

Ithaca2018 Aug. 22 at 2:12 AM

$EBS So happy I added 2K $4.65

0 · Reply

KnuckleSandwich Aug. 21 at 9:48 PM

$EBS just like old time Ms Jes Fye is f’ing EBS?

0 · Reply

ComradeKomisar Aug. 21 at 8:13 PM

$EBS lol. That girl is somethig. Slaps a "sell" rating, but does not disclose a price target. Share price goes up merely on the whiff of resumption of institutional "coverage".

0 · Reply

USAEquityResearch Aug. 21 at 7:31 PM

0 · Reply

Cinderblocks Aug. 21 at 7:31 PM

$EBS Looking good.. There's a gap to fill all the way to$7.

0 · Reply

STACKD0E Aug. 21 at 7:27 PM

$EBS $DFNS $GRML $CLF $RITR 👁

0 · Reply

billywilliamz Aug. 21 at 6:13 PM

$EBS fuggged

0 · Reply

StockTwitsGhost Aug. 21 at 4:28 PM

$EBS JPM resumes coverage with underweight rating. Brought my average down these last few weeks so now sitting in the black for the first time in a long time.

0 · Reply

billywilliamz Aug. 21 at 1:24 PM

$EBS GTCR private equity shoukd take company private

0 · Reply

ShangVXO Aug. 21 at 8:20 AM

$EBS wouldn't mind holding onto this

0 · Reply

Cinderblocks Aug. 20 at 5:52 PM

$EBS Trying to recover from all that selling earlier. Hopefully it can close green. 🤞

0 · Reply

WinstonSmith33 Aug. 20 at 3:57 PM

$EBS great news, you can expect half of the potential order right now...

1 · Reply

Nuesta Aug. 19 at 11:15 PM

$EBS https://globalbiodefense.com/2026/08/19/military-health-researchers-report-advances-in-biosurveillance-and-drug-resistant-infections-at-2026-symposium/ At a military health symposium, BARDA presented interim results from a trial testing whether a half-dose of CYFENDUS could preserve immune response while effectively increasing the number of doses available during an emergency. The reported interim finding was that the half-dose produced an immune response comparable to the full dose.

4 · Reply

GoGetDontGetGot Aug. 19 at 8:18 PM

$EBS well we fishhooked, maybe that will catch some attention and bring in more volume tomorrow for a "Gape up"

0 · Reply

KnuckleSandwich Aug. 19 at 7:14 PM

$EBS if price holds into close...a big whale has set up a bullish position for the run back up to double digits.... pretty sure positive news is leaking and we will know very shortly! 💪

0 · Reply

KnuckleSandwich Aug. 19 at 5:54 PM

$EBS volume is indicating the something very positive is coming our way… there a leak and it’s spilling out green 💥💪🏼🇺🇸🫡

0 · Reply

westparktrader Aug. 19 at 5:07 PM

$EBS that article might have some merit it this thing was trading at ten bucks ... ..

0 · Reply

billywilliamz Aug. 19 at 4:25 PM

$EBS soooo ur saying 2.50 ??

0 · Reply

Market Cap	260.47M
Revenue (ttm)	742.90M
Net Income (ttm)	52.60M
EPS (ttm)	N/A
PE Ratio	3.35
Forward PE	N/A
Profit Margin	7.08%
Debt to Equity Ratio	1.70

Volume	347,947
Avg Vol	1,094,650
Day's Range	N/A - N/A
Shares Out	51.27M
Stochastic %K	97%
Beta	2.35
Analysts	Strong Sell
Price Target	$10.00